- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
International Journal of Vascular Medicine
Volume 2012 (2012), Article ID 162545, 7 pages
Effects of Statins on Cardiorenal Syndrome
1Department of Cardiovascular Medicine, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan
2Department of Medicine and Bioregulatory Sciences, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan
3Department of Pharmacology, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan
4Department of Medical Education, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan
Received 26 April 2012; Accepted 17 May 2012
Academic Editor: David Bishop-Bailey
Copyright © 2012 Shusuke Yagi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cardiovascular disease and renal disease have a close relationship that forms a vicious cycle as a cardiorenal syndrome (CRS). Oxidative stress, endothelial dysfunction, and vascular inflammation could be therapeutic targets when the renin-angiotensin-aldosterone system is activated by accumulation of conventional cardiovascular risk factors; however, a strategy for management of CRS has not been established yet. Statins, HMG-CoA reductase inhibitors, have not only cholesterol-lowering effects but also pleiotropic effects on cardiovascular systems, including anti-inflammatory and antioxidant effects and improvement of nitric oxide bioavailability. Since recent studies have indicated that statins have beneficial effects on chronic kidney disease and heart failure as well as coronary artery disease in cholesterol-lowering-dependent/independent manners, treatment with statins might be a successful strategy for preventing deterioration of CRS.
It is well known that metabolic syndrome contributes directly to the occurrence of cardiovascular events. Accumulation of cardiovascular risk factors, including dyslipidemia, hypertension, and diabetes, activates the renin-angiotensin-aldosterone system (RAAS), leading to not only ischemic cardiovascular disease (CVD) but also left ventricular (LV) dysfunction and chronic kidney disease (CKD) . It is also known that LV dysfunction and renal dysfunction frequently coexist in the same individual. Therefore, it has been advocated that cardiovascular disease and renal disease are closely related to each other as a cardiorenal syndrome (CRS). Disorders of these two organs are co activated and co regulated by various lifestyle-related problems, falling into a vicious cycle of cardiorenal diseases; however, a strategy for management of this syndrome has not been established yet. Therefore, identification of the key therapeutic targets of CRS is needed to break the vicious cycle development of cardiac disease and renal disease.
Statins, HMG-CoA reductase inhibitors, have not only cholesterol-lowering effects but also pleiotropic effects on cardiovascular systems, including anti-inflammatory and antioxidant effects and improvement of nitric oxide (NO) bioavailability [2–5]. In this paper, we focus on the effects of statins on CRS.
2. CRS Is Based on a Close Network between Heart and Kidney Disorders
CRS is defined as “disorders of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other” . Since low cardiac output due to heart failure (HF) leads to decrease in renal blood flow, HF exacerbates renal function. In fact, a 25% decrease in cardiac output leads to a 50% decrease in renal blood flow, and 25% to 40% of patients with decompensated HF experience deterioration in renal function [7, 8]. Renal perfusion is strictly regulated by an autoregulation system to maintain intraglomerular pressure at a constant level; however, prolonged HF evokes glomerular endothelial dysfunction and breakdown of the glomerular autoregulation system. Decrease in renal perfusion due to HF activates the RAAS, leading to cardiorenal damage. It has been reported that patients with CKD, especially elderly patients, are at high risk for major CVD morbidity and mortality. Indeed, the mortality rate in a 2-year interval after acute myocardial infarction is around 50% in patients with stage 5 CKD. In addition, it is noteworthy that patients with CKD have a 10- to 20-fold increased risk of cardiac death [9, 10]. Albuminuria, an early manifestation of CKD, has been shown to be a risk factor for not only the development of CKD but also cardiovascular disease even at stage 1 of CKD . Therefore, CKD is characterized as intraglomerular hypertension and glomerular leakage from albuminuria to overt proteinuria, leading to decrease in glomerular filtration rate (GFR) and ultimately end-stage kidney disease.
Taken together, the heart and kidneys form a tight network in both physiological and pathological conditions, and homeostatic failure of these organs exacerbates clinical states of CKD and CVD in a synergistic manner.
3. Mechanisms of the Development of CRS
The mechanisms of the development of CVD evoked by CKD have not been fully clarified; however, a number of previous studies suggested that several biomarkers yield clues for understanding the mechanisms of the development of CRS. Under normal physiological conditions, oxidative stress and NO bioavailability are each countervailed to maintain vascular homeostasis; however, under pathological conditions such as excessive RAAS activation, this balance is disrupted by an increase of oxidative stress and decrease of NO bioavailability, and disruption of the balance evokes vascular inflammation, leading to cardiovascular remodeling and CKD and eventually to cardiovascular events (Figure 1). Therefore, oxidative stress and NO bioavailability and vascular inflammation could be therapeutic targets for preventing cardiovascular events in addition to conventional risk factors of CVD such as hypertension, diabetes, dyslipidemia, and smoking.
4. Statins Improve Endothelial Function
Endothelial function is important for maintaining vascular homeostasis. Endothelium-derived NO mediates vascular relaxation and inhibits platelet aggregation, vascular smooth muscle proliferation, and endothelium-leukocyte interactions and it protects the cardiovascular system from remodeling [12–14]. On the other hand, accumulation of cardiovascular risk factors impairs endothelial function, which is the earliest manifestation of atherosclerosis. It has been recognized that improvement of endothelial function by statins was observed before a significant reduction in serum cholesterol level, suggesting that these preferable effects of statins on endothelial function are cholesterol-lowering-independent actions [15, 16]. It has been shown that statins increase NO bioavailability by activation and up regulation of endothelial NO synthase (eNOS) through inhibition of Rho/ROCK signaling, activation of the PI3kinase/Akt pathway, and amelioration of eNOS uncoupling [4, 17–21].
5. Statins Decrease Oxidative Stress
Another potential mechanism by which statins may improve endothelial function is their antioxidant effects. Reactive oxygen species (ROS) as a major source of oxidative stress are mainly produced by NADPH oxidase in the cardiovascular system, and Rac-1, a small G protein, has recently been shown to be a key molecule for the assembly and function of NADPH oxidase components . Therefore, NADPH oxidase components, especially Rac-1, could be targets of statin therapy to reduce oxidative stress. In fact, statins attenuate angiotensin II-induced oxidative stress in cardiac myocytes and vascular smooth muscle cells by inhibiting Rac-1-mediated NADH oxidase activity [22, 23]. Statins also reduce mRNA expression of p22phox and Nox1, NADPH oxidase subunits .
6. Statins Ameliorate Vascular Inflammation
It is well known that vascular inflammation plays a central role in the pathogenesis of cardiovascular disease. In addition, it is a widely accepted view that atherosclerosis is a chronic inflammatory disease that is initiated by endothelial cell dysfunction at the vascular surface . Inflammatory cytokines secreted from mononuclear cells such as macrophages and T lymphocytes promote endothelial dysfunction, smooth muscle cell proliferation, and thrombosis. An early step in atherogenesis involves monocyte adhesion to the endothelium and penetration into the subendothelial space. It has been shown that statins reduce expression levels of proinflammatory cytokines and adhesion molecules, including tumor necrosis factor- (TNF)-, interleukin (IL)-1β and IL-6, soluble vascular cell adhesion molecule-1 (sVCAM-1), and von Willebrand factor, and that statins reduce the number of inflammatory cells in atherosclerotic plaques [2, 25–27]. More recently, it has been shown that statins inhibit endothelial exocytosis of Weibel-Palade bodies, endothelial cell granules containing adhesion molecules, in an eNOS-dependent manner and that statins attenuate T cell-mediated myocardial inflammation in a KLF2-dependent manner in a mouse model [27, 28]. The inhibitory effects on endothelial exocytosis and modulation of T-cell function in the immune system may explain the mechanisms of the anti-inflammatory effects of statins in addition to improvement of imbalance between NO bioavailability, and oxidative stress.
Taken together, the results indicate that administration of statins could be a sound strategy for CRS patients with excessive oxidative stress, decreased NO bioavailability and vascular inflammation.
7. Statins for CVD
As for primary prevention against CVD, initial trials of lipid-lowering with clofibrate, cholestyramine, and gemfibrozil failed to reduce coronary mortality [29–31]; however, WOSCOPS , a landmark trial, showed that pravastatin reduced coronary mortality and the following AFCAPS/TexCAPS trial revealed that lovastatin reduced cardiovascular events . In addition, the MEGA trial showed that Japanese hypercholesterolemia patients with no history of coronary disease or stroke, relatively low-risk group for CVD, could benefit from pravastatin for primary prevention against CVD . On the other hand, the 4S and LIPID trials demonstrated that statin therapy improved total mortality as well as morbidity as secondary prevention of CVD [35–37].
The ASTEROID and REVERSAL trials showed that intensive statin therapy in patients with CVD reduced coronary atherosclerotic volume dependent on levels of LDL-C reduction [38, 39]. The PROVE-IT and TNT trials indicated that intensive statin therapy prominently decreased cardiovascular events compared with standard statin therapy in patients with acute or stable CVD, respectively [40, 41].
8. Statins for Systolic HF
The end-stage manifestation of cardiac remodeling due to ischemic and non ischemic heart diseases leads to systolic HF, and it had been expected that statins would be effective for preventing systolic HF. Experimental studies and a meta-analysis showed that a statin ameliorates cardiac remodeling and systolic function [42, 43]; however, two major randomized trials, CORONA and GISSI-HF, failed to reveal beneficial effects of rosuvastatin in patients with systolic HF [44, 45]. These two studies included patients of relatively advanced age who had severe systolic heart failure with/without ischemic heart disease. The CORONA study included patients with ischemic systolic heart failure (mean age of 73 y.o, NYHA class II to IV, mean LV ejection fraction of 31%), and the GISSI-HF study included over 60% of subjects with non-ischemic heart disease (mean age of 68 y.o. NYHA class II to IV, mean LV ejection fraction of 33%), suggesting that a statin is not effective for severe systolic HF in patients with both ischemic and non-ischemic heart diseases. Post-hoc analysis of the results of these studies showed that a statin was effective with patients in a low N terminal-pro B type natriuretic peptide (NT-proBNP) group (<103 pmol/L: 868 pg/mL) and in a high-sensitivity CRP (hs-CRP) group (> or = 2.0 mg/L) [46, 47]. These results indicate that statin treatment is effective in patients with early-stage cardiac injury but not in patients with advanced-stage cardiac injury and that statin therapy is more beneficial in HF patients with increased hs-CRP.
9. Statins for Diastolic HF
LV diastolic dysfunction is an early manifestation of cardiac remodeling, and statins prevent cardiac remodeling including cardiac fibrosis and hypertrophy. Therefore, there is a possibility that statins improve LV diastolic function. Several experimental and observational studies showed the effectiveness of a statin for LV diastolic function [48–51]. In addition, a randomized controlled small trial of statin therapy in patients with diastolic HF (statin group, ; no statin group, ) showed that a statin improved survival in patients with diastolic HF during a 5-year follow-up period . Since other antioxidant agents such as RAAS inhibitors have some beneficial effects on cardiac diastolic function, there is a possibility that statins might work for improving cardiac diastolic function via attenuation of oxidative stress.
10. Statins for Atrial Function
Elevated cardiac end-diastolic pressure due to cardiac diastolic dysfunction plays a central role in atrial remodeling, leading to atrial fibrillation (AF) and cardiogenic embolism. Although antiarrhythmic and anticoagulant agents are used for these pathological conditions, these drugs are not able to ameliorate atrial remodeling. It has been reported that structural and electrophysiological changes in the atrium are associated with inflammation and oxidative stress . It has also been reported that statins reduce the incidence of AF through attenuation of atrial remodeling . A meta-analysis suggested an antiarrhythmic effect of statins against AF, especially under conditions of increased inflammation such as post-operative cardiac surgery and acute coronary syndromes . These studies indicate that statin therapy prevents not only LV remodeling but also atrial structural and electrical remodeling, leading to decrease in the incidence of AF and cardiogenic embolism.
11. Statins for CVD in Patients with CKD
Mild to moderate CKD is associated with increased cardiovascular risk. Therefore, strict management of serum lipid profile by statins also seems to be effective for reducing cardiovascular events in patients with mild to moderate CKD. A meta-analysis showed that statins reduce all-cause mortality, cardiovascular death, and non fatal cardiovascular events in mild to moderate CKD patients . Post-hoc subgroup analysis of the Treating to New Targets (TNT) trial showed that a high dose of atorvastatin (80 mg) reduced cardiovascular events more than did a low dose of atorvastatin (10 mg) .
Although the SHARP trial, a randomized large-scale trial, has directly shown that simvastatin plus ezetimibe reduced the incidence of major vascular events in patients with CKD compared with placebo, the 4-D, AURORA, and SHARP trials showed no definite clinical benefit of statin monotherapy in hemodialysis patients regardless of significant reductions in LDL-C [57, 58]. These findings indicate that a statin is no longer able to reduce cardiovascular events in end-stage CKD, and statin therapy should therefore be recommended to CKD patients with mild to moderate CKD.
12. Statins for Renal Function
Experimental studies showed that hyperlipidemia is a risk factor for renal disease: cholesterol loading enhances glomerular injury and the decrease in serum lipid level by statins slows the rate of renal injury progression [59, 60]. Deposition of lipids in glomeruli and activation of the RAAS by accumulation of CVD risk factors cause glomerular endothelial dysfunction and increase intraglomerular pressure, leading to tangible albuminuria, an early manifestation of proteinuria, and decrease in glomerular filtration rate (GFR). Since albuminuria also directly injures glomeruli by itself, reduction of albuminuria might be essential to prevent progression of CKD. Animal studies have shown renal protective actions of statins [61, 62]; however, there are conflicting data concerning the effects of statins on renal function. In a clinical setting, two meta-analyses have shown that statins decrease albuminuria [63, 64]; whereas, other studies have shown that there were no significant effects of statins on albuminuria [65–67]. Additional evidence is needed to apply statin administration for treatment of CKD.
13. Beneficial Effects of Pitavastatin, a New Lipophilic Strong Statin
It has not been established whether the beneficial effects of statins on cardiorenal tissues are class effects; however, lipophilic statins seem to have direct effects on cardiovascular organs. The newly developed drug pitavastatin, a lipophilic and a strong statin, is effective for lowering LDL-cholesterol and increasing high-density lipoprotein cholesterol (HDL-C), which are preferable in the serum lipid profile for preventing CVD. In terms of tissue distribution of statins, pharmacokinetic profile before and after liver metabolism is an important consideration. Most of pitavastatin is absorbed following ingestion (80%), and its level of protein binding is extremely high (>95%) . In addition, pitavastatin is hardly metabolized by cytochrome p450 (CYP), and most of the bioavailable pitavastatin is excreted in an unchanged form in bile and enters enterohepatic circulation by reabsorption in the small intestine . Therefore, bioavailable pitavastatin is able to be distributed directly to cardiovascular and renal tissues directly and exerts cardiorenal protective effects. From these facts, pitavastatin has been expected to have stronger pleiotropic effects than those of other classical statins. In fact, it has been reported that pitavastatin has anti-oxidant and anti-inflammatory effects and that it improves NO bioavailability, leading to improvement of cardiorenal function [70–78]. Minimal interaction with CYP suggests that pitavastatin is safer than other statins regardless of lipophilicity.
14. Pitavastatin Ameliorates CRS
Our previous experimental data showed that pitavastatin treatment improved angiotensin II-induced LV remodeling, renal insufficiency, atrial remodeling, incidence of AF, and atrial prothrombotic condition in eNOS knockout mice [79, 80]. In that study, we concluded that pitavastatin exerts eNOS-independent protective actions against angiotensin II-induced cardiovascular remodeling and renal insufficiency through inhibition of the transforming growth factor- (TGF)- 1-Smad 2/3 signaling pathway by suppression of oxidative stress [79, 80]. In addition, our clinical study showed that a low dose (1 mg/day) of pitavastatin improved LV diastolic function and reduced albuminuria . In that study, statistical analysis demonstrated that the effect of pitavastatin on cardiorenal protection was associated with reduction of oxidative stress but not reduction of LDL-C .
Pitavastatin might have more overt pleiotropic effects, especially on reduction of oxidative stress, than those of other statins. A large clinical trial is needed to confirm the effects of pitavastatin on CRS.
Accumulation of CVD risk factors leads to activation of the RAAS, which exacerbates CRS with inflammation and eventually evokes cardiovascular events. Statin therapy plays an important role in prevention of these cardiovascular and renal events. Early use of statins is recommended in patients with multiple cardiovascular risk factors before the development of irreversible cardiorenal remodeling.
This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, a Grant from the Mitsui Life Social Welfare Foundation, and a Grant for a Study Group on Aseptic Femoral Neck Necrosis from the Ministry of Health, Labour and Welfare of Japan.
- L. G. Bongartz, M. J. Cramer, P. A. Doevendans, J. A. Joles, and B. Braam, “The severe cardiorenal syndrome: 'Guyton revisited',” European Heart Journal, vol. 26, no. 1, pp. 11–17, 2005.
- K. Node, M. Fujita, M. Kitakaze, M. Hori, and J. K. Liao, “Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy,” Circulation, vol. 108, no. 7, pp. 839–843, 2003.
- S. Wassmann, U. Laufs, K. Müller et al., “Cellular antioxidant effects of atorvastatin in vitro and in vivo,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 2, pp. 300–305, 2002.
- S. Wolfrum, K. S. Jensen, and J. K. Liao, “Endothelium-dependent effects of statins,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 5, pp. 729–736, 2003.
- U. Laufs, F. Custodis, and M. Böhm, “HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk,” Drugs, vol. 66, no. 2, pp. 145–154, 2006.
- C. Ronco, P. McCullough, S. D. Anker et al., “Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative,” European Heart Journal, vol. 31, no. 6, pp. 703–711, 2010.
- A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C. Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” The New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1305, 2004.
- S. Merhaut and R. J. Trupp, “Cardiorenal dysfunction,” AACN Advanced Critical Care, vol. 21, no. 4, pp. 357–364, 2010.
- D. S. Keith, G. A. Nichols, C. M. Gullion, J. B. Brown, and D. H. Smith, “Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization,” Archives of Internal Medicine, vol. 164, no. 6, pp. 659–663, 2004.
- B. M. Wall, “Cardiorenal risk factors,” The American Journal of the Medical Sciences, vol. 340, pp. 25–29, 2010.
- H. L. Hillege, V. Fidler, G. F. H. Diercks et al., “Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population,” Circulation, vol. 106, no. 14, pp. 1777–1782, 2002.
- L. J. Ignarro, G. M. Buga, K. S. Wood, R. E. Byrns, and G. Chaudhuri, “Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 24, pp. 9265–9269, 1987.
- U. C. Garg and A. Hassid, “Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells,” Journal of Clinical Investigation, vol. 83, no. 5, pp. 1774–1777, 1989.
- P. Kubes, M. Suzuki, and D. N. Granger, “Nitric oxide: an endogenous modulator of leukocyte adhesion,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 11, pp. 4651–4655, 1991.
- T. J. Anderson, I. T. Meredith, A. C. Yeung, B. Frei, A. P. Selwyn, and P. Ganz, “The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion,” The New England Journal of Medicine, vol. 332, no. 8, pp. 488–493, 1995.
- G. O'Driscoll, D. Green, and R. R. Taylor, “Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month,” Circulation, vol. 95, no. 5, pp. 1126–1131, 1997.
- U. Laufs, V. la Fata, J. Plutzky, and J. K. Liao, “Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors,” Circulation, vol. 97, no. 12, pp. 1129–1135, 1998.
- Y. Kureishi, Z. Luo, I. Shiojima et al., “The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals,” Nature Medicine, vol. 6, no. 9, pp. 1004–1010, 2000.
- M. Endres, U. Laufs, Z. Huang et al., “Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 15, pp. 8880–8885, 1998.
- S. Wolfrum, M. Grimm, M. Heidbreder et al., “Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme a reductase inhibitor is mediated by endothelial nitric oxide synthase,” Journal of Cardiovascular Pharmacology, vol. 41, no. 3, pp. 474–480, 2003.
- U. Forstermann and H. Li, “Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling,” vol. 164, pp. 213–223.
- M. Takemoto, K. Node, H. Nakagami et al., “Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy,” Journal of Clinical Investigation, vol. 108, no. 10, pp. 1429–1437, 2001.
- S. Wassmann, U. Laufs, A. T. Bäumer et al., “Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase,” Molecular Pharmacology, vol. 59, no. 3, pp. 646–654, 2001.
- R. Ross, “The pathogenesis of atherosclerosis: a perspective for the 1990s,” Nature, vol. 362, no. 6423, pp. 801–809, 1993.
- R. S. Rosenson, “Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy,” American Journal of Cardiovascular Drugs, vol. 1, no. 6, pp. 411–420, 2001.
- D. Tousoulis, C. Antoniades, E. Bosinakou et al., “Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure,” Atherosclerosis, vol. 178, no. 2, pp. 359–363, 2005.
- M. Yamakuchi, J. J. M. Greer, S. J. Cameron et al., “HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size,” Circulation Research, vol. 96, no. 11, pp. 1185–1192, 2005.
- D. X. Bu, M. Tarrio, N. Grabie et al., “Statin-induced Kruppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses,” Journal of Clinical Investigation, vol. 120, no. 6, pp. 1961–1970, 2010.
- M. F. Oliver, J. A. Heady, J. N. Morris, and J. Cooper, “W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the committee of principal investigators,” The Lancet, vol. 2, no. 8191, pp. 379–385, 1980.
- “The lipid research clinics coronary primary prevention trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering,” Journal of the American Medical Association, vol. 251, no. 3, pp. 365–374, 1984.
- M. H. Frick, O. Elo, and K. Haapa, “Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease,” The New England Journal of Medicine, vol. 317, no. 20, pp. 1237–1245, 1987.
- J. Shepherd, S. M. Cobbe, I. Ford, et al., “Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of scotland coronary prevention study group,” The New England Journal of Medicine, vol. 333, pp. 1301–1307, 1995.
- J. R. Downs, M. Clearfield, S. Weis et al., “Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS,” Journal of the American Medical Association, vol. 279, no. 20, pp. 1615–1622, 1998.
- H. Nakamura, K. Arakawa, H. Itakura et al., “Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial,” The Lancet, vol. 368, no. 9542, pp. 1155–1163, 2006.
- T. R. Pedersen, “Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4s),” The Lancet, vol. 344, no. 8934, pp. 1383–1389, 1994.
- “Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischaemic disease (lipid) study group,” The New England Journal of Medicine, vol. 339, pp. 1349–1357, 1998.
- F. M. Sacks, M. A. Pfeffer, L. A. Moye et al., “The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators,” The New England Journal of Medicine, vol. 335, pp. 1001–1009, 1996.
- S. E. Nissen, S. J. Nicholls, I. Sipahi et al., “Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial,” Journal of the American Medical Association, vol. 295, no. 13, pp. 1556–1565, 2006.
- S. E. Nissen, E. M. Tuzcu, P. Schoenhagen et al., “Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial,” Journal of the American Medical Association, vol. 291, no. 9, pp. 1071–1080, 2004.
- C. P. Cannon, E. Braunwald, C. H. McCabe et al., “Intensive versus moderate lipid lowering with statins after acute coronary syndromes,” The New England Journal of Medicine, vol. 350, no. 15, pp. 1495–1504, 2004.
- J. C. LaRosa, S. M. Grundy, D. D. Waters et al., “Intensive lipid lowering with atorvastatin in patients with stable coronary disease,” The New England Journal of Medicine, vol. 352, no. 14, pp. 1425–1435, 2005.
- U. Landmesser, N. Engberding, F. H. Bahlmann et al., “Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase,” Circulation, vol. 110, no. 14, pp. 1933–1939, 2004.
- L. Zhang, S. Zhang, H. Jiang, A. Sun, Y. Zou, and J. Ge, “Effects of statin treatment on cardiac function in patients with chronic heart failure: a meta-analysis of randomized controlled trials,” Clinical Cardiology, vol. 34, no. 2, pp. 117–123, 2011.
- J. Kjekshus, E. Apetrei, V. Barrios et al., “Rosuvastatin in older patients with systolic heart failure,” The New England Journal of Medicine, vol. 357, no. 22, pp. 2248–2261, 2007.
- L. Tavazzi, A. P. Maggioni, R. Marchioli et al., “Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomise, double-blind, placebo-controlled trial,” The Lancet, vol. 372, pp. 1231–1239, 2008.
- J. J. V. McMurray, J. Kjekshus, L. Gullestad et al., “Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA): a retrospective analysis,” Circulation, vol. 120, no. 22, pp. 2188–2196, 2009.
- J. G. F. Cleland, J. J. V. McMurray, J. Kjekshus et al., “Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from corona (controlled rosuvastatin multinational trial in heart failure),” Journal of the American College of Cardiology, vol. 54, no. 20, pp. 1850–1859, 2009.
- D. Mannheim, J. Herrmann, P. O. Bonetti, R. Lavi, L. O. Lerman, and A. Lerman, “Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect,” Atherosclerosis, vol. 216, no. 2, pp. 283–291, 2011.
- S. A. Chang, Y. J. Kim, H. W. Lee et al., “Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy,” Hypertension, vol. 54, no. 3, pp. 591–597, 2009.
- Z. Xu, H. Okamoto, M. Akino, H. Onozuka, Y. Matsui, and H. Tsutsui, “Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice,” Journal of Cardiovascular Pharmacology, vol. 51, no. 1, pp. 62–70, 2008.
- H. Fukuta, D. C. Sane, S. Brucks, and W. C. Little, “Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report,” Circulation, vol. 112, no. 3, pp. 357–363, 2005.
- F. Tehrani, R. Morrissey, A. Phan, C. Chien, and E. R. Schwarz, “Statin therapy in patients with diastolic heart failure,” Clinical Cardiology, vol. 33, no. 4, pp. E1–E5, 2010.
- P. Santangeli, G. Ferrante, G. Pelargonio et al., “Usefulness of statins in preventing atrial fibrillation in patients with permanent pacemaker: a systematic review,” Europace, vol. 12, no. 5, pp. 649–654, 2010.
- L. Fauchier, B. Pierre, A. de Labriolle, C. Grimard, N. Zannad, and D. Babuty, “Antiarrhythmic effect of statin therapy and atrial fibrillation. A meta-analysis of randomized controlled trials,” Journal of the American College of Cardiology, vol. 51, no. 8, pp. 828–835, 2008.
- S. D. Navaneethan, F. Pansini, V. Perkovic et al., “HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD007784, 2009.
- J. Shepherd, J. J. P. Kastelein, V. Bittner et al., “Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease. The TNT (treating to new targets) study,” Journal of the American College of Cardiology, vol. 51, no. 15, pp. 1448–1454, 2008.
- W. März, B. Genser, C. Drechsler et al., “Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 6, pp. 1316–1325, 2011.
- B. C. Fellstrom, A. G. Jardine, R. E. Schmieder et al., “Rosuvastatin and cardiovascular events in patients undergoing hemodialysis,” The New England Journal of Medicine, vol. 360, pp. 1395–1407, 2009.
- W. F. Keane, “Lipids and the kidney,” Kidney International, vol. 46, no. 3, pp. 910–920, 1994.
- R. Rubin, S. Silbiger, L. Sablay, and J. Neugarten, “Combined antihypertensive and lipid-lowering therapy in experimental glomerulonephritis,” Hypertension, vol. 23, no. 1, pp. 92–95, 1994.
- M. Fujii, T. Inoguchi, Y. Maeda et al., “Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice,” Kidney International, vol. 72, no. 4, pp. 473–480, 2007.
- X. M. Liang, H. Otani, Q. Zhou et al., “Renal protective effects of pitavastatin on spontaneously hypercholesterolaemic Imai Rats,” Nephrology Dialysis Transplantation, vol. 22, no. 8, pp. 2156–2164, 2007.
- K. Douglas, P. G. O'Malley, and J. L. Jackson, “Meta-analysis: the effect of statins on albuminuria,” Annals of Internal Medicine, vol. 145, no. 2, pp. 117–124, 2006.
- G. F. M. Strippoli, S. D. Navaneethan, D. W. Johnson et al., “Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials,” BMJ, vol. 336, no. 7645, pp. 645–651, 2008.
- J. Atthobari, A. H. Brantsma, R. T. Gansevoort et al., “The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study,” Nephrology Dialysis Transplantation, vol. 21, no. 11, pp. 3106–3114, 2006.
- P. Ruggenenti, A. Perna, M. Tonelli et al., “Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 11, pp. 1928–1938, 2010.
- V. G. Athyros, D. P. Mikhailidis, A. A. Papageorgiou et al., “The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study,” Journal of Clinical Pathology, vol. 57, no. 7, pp. 728–734, 2004.
- Y. Saito, “Pitavastatin: an overview,” Atherosclerosis Supplements, vol. 12, pp. 271–276, 2011.
- A. M. Gotto Jr. and J. Moon, “Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia,” Expert Review of Cardiovascular Therapy, vol. 8, no. 8, pp. 1079–1090, 2010.
- T. Nakamura, T. Sugaya, Y. Kawagoe, Y. Ueda, S. Osada, and H. Koide, “Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy,” Diabetes Care, vol. 28, no. 11, pp. 2728–2732, 2005.
- K. Arao, T. Yasu, T. Umemoto et al., “Effects of pitavastatin on fasting and postprandial endothelial function and blood rheology in patients with stable coronary artery disease,” Circulation Journal, vol. 73, no. 8, pp. 1523–1530, 2009.
- E. Kibayashi, M. Urakaze, C. Kobashi et al., “Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein- induced interleukin-8 production in human aortic endothelial cells,” Clinical Science, vol. 108, no. 6, pp. 515–521, 2005.
- T. Hiro, T. Kimura, T. Morimoto et al., “Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study),” Journal of the American College of Cardiology, vol. 54, no. 4, pp. 293–302, 2009.
- S. Morikawa, W. Takabe, C. Mataki et al., “The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells,” Journal of Atherosclerosis and Thrombosis, vol. 9, no. 4, pp. 178–183, 2002.
- J. Wang, T. Tokoro, K. Matsui, S. Higa, and I. Kitajima, “Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells,” Life Sciences, vol. 76, no. 19, pp. 2257–2268, 2005.
- Y. Mizuguchi, Y. Oishi, H. Miyoshi, A. Iuchi, N. Nagase, and T. Oki, “Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia,” Circulation Journal, vol. 72, no. 4, pp. 538–544, 2008.
- T. Aoyagi, F. Nakamura, T. Tomaru, and T. Toyo-Oka, “Beneficial effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac function in ischemic and nonischemic heart failure,” International Heart Journal, vol. 49, no. 1, pp. 49–58, 2008.
- K. Kimura, H. Shimano, K. Yokote, M. Urashima, and T. Teramoto, “Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO effectiveness and safety (LIVES) study,” Journal of Atherosclerosis and Thrombosis, vol. 17, no. 6, pp. 601–609, 2010.
- S. Yagi, K. I. Aihara, Y. Ikeda et al., “Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II-induced cardiovascular remodeling and renal insufficiency,” Circulation Research, vol. 102, no. 1, pp. 68–76, 2008.
- S. Yagi, M. Akaike, K. I. Aihara et al., “Endothelial nitric oxide synthase-independent protective action of statin against angiotensin ii-induced atrial remodeling via reduced oxidant injury,” Hypertension, vol. 55, no. 4, pp. 918–923, 2010.
- S. Yagi, M. Akaike, K. I. Aihara et al., “Effect of low-dose (1 mg/day) pitavastatin on left ventricular diastolic function and albuminuria in patients with hyperlipidemia,” American Journal of Cardiology, vol. 107, no. 11, pp. 1644–1649, 2011.